Hemodialysis

ECHO: Offering New Life to Coronavirus Patients Struggling to Breathe

Tuesday, May 26, 2020 - 1:33pm

LACEY, Wash., May 26, 2020 /PRNewswire/ -- A medical device company in Washington State has developed a process that will breathe life into and provide hope to those battling the Coronavirus.

Key Points: 
  • LACEY, Wash., May 26, 2020 /PRNewswire/ -- A medical device company in Washington State has developed a process that will breathe life into and provide hope to those battling the Coronavirus.
  • It converts the life-saving functions of the FDA-approved Extracorporeal Membrane Oxygenation (ECMO) circuit on to the FDA-approved hemodialysis machine.
  • The Associated Press recently reported New York City officials as saying at least 80% of Coronavirus patients who were put on ventilators ultimately died.
  • The idea for ECHO was inspired by the effectiveness of ECMO in treating Coronavirus patients.

Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®

Tuesday, May 26, 2020 - 1:15pm

Through the Expanded Access protocol, an infected central venous catheter can now be treated with Citius' Mino-Lok, potentially avoiding the need for the removal and replacement procedure.

Key Points: 
  • Through the Expanded Access protocol, an infected central venous catheter can now be treated with Citius' Mino-Lok, potentially avoiding the need for the removal and replacement procedure.
  • Given the challenges at today's hospitals, the patients, the hospital staff, and the hospital system at large stand to benefit greatly from free access to the Mino-Lok solution.
  • Mino-Lok is currently in a Phase 3 clinical trial for the treatment of central line-associated bloodstream infections (CLABSIs).
  • CLABSIs/CRBSIsare very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge.

Rockwell Medical, Inc. Files New Drug Submission with Health Canada for Marketing Approval of Triferic® AVNU™

Tuesday, May 26, 2020 - 12:00pm

If approved by Health Canada, we expect Triferic AVNU to be an important new treatment option for dialysis clinics and the patients they serve.

Key Points: 
  • If approved by Health Canada, we expect Triferic AVNU to be an important new treatment option for dialysis clinics and the patients they serve.
  • Rockwell Medical has a distribution agreement with RMC Canada, through which Rockwell Medical will receive a transfer price based on Triferic sales in Canada, subject to Canadian regulatory approval.
  • Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
  • Triferic is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office.

The L-Carnitine market was valued at US$ 47.1 million in 2018 and is projected to reach US$ 72.7 million by 2027; it is expected to grow at a CAGR of 4.9% from 2019 to 2027

Saturday, May 23, 2020 - 1:20am

It is also approved to treat Carnitine deficiencies in patients at the end stage of renal diseases, undergoing hemodialysis..

Key Points: 
  • It is also approved to treat Carnitine deficiencies in patients at the end stage of renal diseases, undergoing hemodialysis..
  • Besides its uses in human nutrition, L-Carnitine is also used as an additive in animal feed formulations.
  • Ltd; Lonza Group Ltd; Northeast Pharmaceutical Group Co., Ltd; Merck KGaA; and Biosint S.p.A., has bolstered the growth of the L-Carnitine market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis

Thursday, May 21, 2020 - 1:35pm

This study was a multicenter, open-label study in patients with severe CKD with and without hemodialysis.

Key Points: 
  • This study was a multicenter, open-label study in patients with severe CKD with and without hemodialysis.
  • KBP-5074 was generally well tolerated in both hemodialysis (N=6) and non-hemodialysis (N=5) patients.
  • During the hemodialysis, the AUCs for inlet and outlet samples were similar, indicating minimal impact of hemodialysis on drug concentrations.
  • We are encouraged by the safety and PK results seen in in this study of patients with severe CKD with and without hemodialysis.

Analysis on Impact of COVID19-Hemodialysis Equipment Market 2020-2024 | Shortage in Availability of Kidneys for Transplant to Boost Growth | Technavio

Monday, May 18, 2020 - 9:15am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40103

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40103
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our hemodialysis equipment market report covers the following areas:
    This study identifies technological advances and new product launches as the prime reasons driving the hemodialysis equipment market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the hemodialysis equipment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

United States Vascular Access Devices and Accessories Industry 2020-2026 - Market Trends & Developments, Procedure Numbers, Competitive Analysis

Wednesday, May 6, 2020 - 12:00pm

DUBLIN, May 6, 2020 /PRNewswire/ -- The "Vascular Access Devices and Accessories Market Report Suite | United States | 2020-2026 | Medsuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 6, 2020 /PRNewswire/ -- The "Vascular Access Devices and Accessories Market Report Suite | United States | 2020-2026 | Medsuite" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. market for vascular access includes both medical devices intended to access a patient's veins and arteries and accessories intended to improve safety and performance.
  • Catheters are used for a variety of functions, including administering drugs, drawing blood, and specialized treatments like hemodialysis.
  • Vascular access catheters can be inserted either peripherally in a patient's arm or centrally, such as in the patient's jugular.

Dialyze Direct Expands Footprint within CareRite Centers Network

Tuesday, May 5, 2020 - 3:15pm

BROOKLYN, N.Y., May 5, 2020 /PRNewswire/ --Dialyze Direct, a leader in staff-assisted home dialysis services, announced plans for further expansion of its in-house skilled nursing dialysis service with CareRite Centers, the leading subacute and skilled nursing network within the nation.

Key Points: 
  • BROOKLYN, N.Y., May 5, 2020 /PRNewswire/ --Dialyze Direct, a leader in staff-assisted home dialysis services, announced plans for further expansion of its in-house skilled nursing dialysis service with CareRite Centers, the leading subacute and skilled nursing network within the nation.
  • The CareRite Centers network spans from New York, New Jersey, Florida, and Tennessee; currently, Dialyze Direct operates within the CareRite network at The Chateau at Brooklyn Rehabilitation and Nursing Center in New York.
  • Dialyze Direct is a leading kidney care innovation company, pioneering breakthrough solutions for patients suffering from kidney disease.
  • Dialyze Direct has created a staff-assisted home hemodialysis model resulting in significantly improved patient outcomes and quality of life while substantially decreasing costs for payors.

Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Tuesday, April 28, 2020 - 9:10pm

Interim analysis of safety data in 70 patients in this clinical trial evaluating a 4-dose regimen of HEPLISAV-B in adults with end-stage renal disease (ESRD) who are initiating or undergoing hemodialysis, showed HEPLISAV-B was well tolerated with a seroprotection rate of 86.4% in 44 patients.

Key Points: 
  • Interim analysis of safety data in 70 patients in this clinical trial evaluating a 4-dose regimen of HEPLISAV-B in adults with end-stage renal disease (ESRD) who are initiating or undergoing hemodialysis, showed HEPLISAV-B was well tolerated with a seroprotection rate of 86.4% in 44 patients.
  • We are pleased with these interim results from the hemodialysis trial which reinforce the existing clinical data set regarding the safety and rates of protection provided by HEPLISAV-B, commented Robert Janssen , MD, Chief Medical Officer at Dynavax.
  • The study is designed to evaluate HEPLISAV-Bs immunogenicity at study week 20 and safety over the 68-week study duration.
  • Safety and effectiveness of a 4-dose regimen of HEPLISAV-B have not been established in adults on hemodialysis.

InventHelp Inventor Develops Improved Dialysis Heating Device (CBA-3670)

Tuesday, April 21, 2020 - 3:30pm

The invention provides an effective way to warm the fluid used in peritoneal dialysis.

Key Points: 
  • The invention provides an effective way to warm the fluid used in peritoneal dialysis.
  • In doing so, it offers an improved alternative to traditional prewarming methods.
  • The invention features a simple design that is convenient and easy to use so it is ideal for individuals who utilize peritoneal dialysis.
  • "My design ensures that dialysis fluid is the correct temperature for patient comfort."